Overview

Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and outcomes associated between the two treatment modalities
Phase:
Phase 4
Details
Lead Sponsor:
Wake Forest University Health Sciences
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Vancomycin